Venture Capital News: Flare Therapeutics Secures $85M Series C Round
2026-07-09
Tweet
CAMBRIDGE, MA, Flare Therapeutics, a clinical-stage biotechnology company, announced the closing of an $85 million Series C financing.
Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover and develop precision medicines, announced the closing of an $85 million Series C financing led by existing investors. In connection with the financing, the company also announced the appointment of Anna Protopapas as Chief Executive Officer.
The financing was led by Third Rock Ventures and Nextech Invest and included participation from Pfizer Ventures, Boxer Capital, GordonMD Global InvestmentsĀ® LP, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital and Eventide Asset Management. Proceeds from the financing will be used to advance the Company's prioritized programs, as well as for working capital and general corporate purposes.
The financing was led by Third Rock Ventures and Nextech Invest and included participation from Pfizer Ventures, Boxer Capital, GordonMD Global InvestmentsĀ® LP, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital and Eventide Asset Management. Proceeds from the financing will be used to advance the Company's prioritized programs, as well as for working capital and general corporate purposes.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
